the process of drug discovery has evolved considerably since the advent of high-throughput screening (htS) in the 1980s. experts and opinion leaders today are agreeing that the current trend in the field is a focus on increasing overall quality (target, screening, and compounds), use of multiple screening approaches for lead discovery, and more flexibility in the process. the associated need for increased flexibility and quality control to support existing htS paradigms as well as lower throughput approaches such as fragment screening, computational chemistry, focused library building, and centralized lead optimization support has required an evolution in compound management (cm, aka sample management or library management). although there is much less published peer-reviewed data in cm, due to its historical links to htS, it has followed very similar trends. in recent years, the focus in cm has been increasingly in compound quality and increased flexibility of the process, as opposed to number of compounds dispensed and speed of dispensing, which were standard metrics and indicators used not so long ago. ideally, to screen the highest quality sample for every assay, one would start with a correct identity and pure solid, make a correct concentration solution in water or water-soluble/assay-compatible solvent that would allow 100% solubilization, and screen it immediately in a biological assay. neither cm nor screening has advanced sufficiently to deliver this ideal scenario, but many significant advancements have been made in recent years both in terms of quality of compounds in stores and flexibility of the process, which will be reviewed herein. (Journal of Biomolecular Screening 2009:444-451) 
INTRODUCTION
T he field of compound management (cm) came into being as a requisite for high-throughput screening (htS) but has grown into a stand-alone discipline. 32 in the 1970s and 1980s, htS grew to prominence, 3, 7 and the drug discovery industry moved from a paradigm of testing compounds as they were synthesized (or extracted/isolated in the case of natural products) to one where a set collection was tested across a group of targets. 1,2,4 this business change was driven by the need for chemical templates for new drug targets 20 and the fond hope that these templates would already exist within a company's powder compound collection. as htS increased and the then new field of combinatorial chemistry came into vogue, 24 the sizes of compound collections grew, 9 and the logistics of managing these collections became an issue of paramount importance. 25, 54, 56 interestingly, as htS has grown, it has become more integrated into the discovery process 12 and is now simply one of the tools and approaches that may be used to find bioactive molecules. 8, 13 as one review puts it, "htS is [now] only a name for specific developments in laboratory automation to collect a large amount of experimental data in a relatively short time." 3 alternate and complementary approaches such as virtual screening, 10, 22 fragment screening, 19 focused library testing, 21 compound pooling, 18 template-based design, 23 or combinations of the above 11, 17 are applied in parallel or serially as appropriate, but all are seen as synergistic parts of a full discovery program.
Similarly, as discovery efforts have become more sophisticated, 24 the need for cm services has grown. 11, 56 this began with the extension of htS techniques into the later phases of lead discovery such as hit to lead and lead optimization but has now expanded to all parts of the discovery pipeline. 1,2,4 the reasons are both obvious and subtle; the need to have compounds supplied in a timely fashion and in the correct format for testing seems obvious, but until the necessary infrastructure has been established, researchers in departments outside htS have had other systems in place to meet this need. When combined with increased globalization and increasingly stringent data quality and integrity requirements, cm has 1 center for integrative chemical biology and drug discovery, eshelman School of pharmacy, university of north carolina at chapel hill. become a vital, though often underappreciated, part of every discovery effort.
QUALITY CONSIDERATIONS IN COMPOUND MANAGEMENT
early cm systems were created to manage the logistics of htS. 7, 28, 29 often, these systems replaced entirely manual operations with only rudimentary inventory systems. the focus of cm was to provide 96-well microplates to htS in a standard format. 7 although this now seems a very simple cm operation, at the time it required massive efforts to manually solubilize compound collections, transfer them to microplates, and manage the replication. multiple solvent systems were evaluated prior to the selection of dmSo as a nearly universal solvent, and automation systems specific to cm had to be developed. although there was considerable care expended in maintaining sample integrity, the main focus was on 100% sample tracking accuracy and throughput. it was not uncommon to hear the phrase "it's only screening" when the question of quality was raised.
thankfully, the focus of discovery, particularly htS, has now shifted toward efficiency and quality in all aspects of the process. 1,2 increasingly, htS is striving to create data with sufficient quality to generate structure-activity relationship (SaR) quality data from primary screens. 109 Quality is now a watchword in all phases of the discovery process, and this carried into the cm process. from the number of publications regarding compound and process quality, there appears to be a maintained presence and interest when compared to general cm papers, as shown in Figure 1 .
there are 3 primary sources of error in any biological result where a chemical compound is tested ( Fig. 2 
):
• biological assay error-the assay error resulting from assay constituents, technologies, and detection methodologies and the associated potential error from biological material production are the most closely monitored source of variance and have been studied rigorously elsewhere (see makarenkov et al. 6 and references therein) and will not be addressed here. • chemical error-this relates to any errors that result from the chemical sample itself, most commonly concentration, purity, and structural identity. • process error-includes identity mismatches resulting from sample tracking errors, weighing and liquid handling errors, sample contamination, and sample degradation due to storage and/or handling and analytical measurement error.
CHEMICAL ERROR
the most obvious type of chemical error results from error in the structure of the molecule. errors of this type can result from improper structural identification (i.e., the wrong structure is associated with the sample), initial purity and subsequent degradation during storage or handling, or misdrawn structures. in today's discovery environment, misdrawn structures are rare. this is largely due to the wide use of electronic drawing and registration systems and has been further improved by the use of electronic laboratory notebooks to track the entire synthesis procedure. today's chemist rarely, if ever, draws a structure for registration by hand, and the redrawing of structures by dedicated registration services is rarer still, thus removing a major error source from chemical databases. chemists also have access to sophisticated analytical tools such as nuclear magnetic resonance (nmR) and liquid chromatography/mass spectrometry (lc/mS) to verify that the structure they draw is what is actually in the tube they submit. moreover, the use of analytical quality control (Qc) to check for compound identity is now routine, 76 so even the low number of incidences where the chemist registered the wrong structure gets corrected usually before any biological data have been posted for that compound.
the purity of these samples is another issue. chemists in the early 20th century always checked sample purity, albeit by cruder methods, such as thin-layer chromatography (tlc) and melting point, but there was significant pride in their work product that kept sample purity very high. during the early days of combinatorial chemistry, this changed. it became possible to make large numbers of compounds using parallel synthesis, but commensurate large-scale purification techniques did not exist. it was deemed better to accept the low-purity compounds than to not take advantage of a potential source of huge numbers of compounds and a technique that was the darling of the scientific media and thought to be the savior of research productivity. once the bar had been lowered for combi-chem samples, it was not a great leap to do the same for all screening samples. this led to a situation where highly impure samples were commonplace in cm stores and confirmation of activity became a major bottleneck. fortunately, technology and reason caught up nearly simultaneously (see Ripka et al. 69 and references therein). With the advent of highthroughput lc/mS and improved parallel synthesis techniques in the 1990s, it became not only possible but a requisite to purify all samples prior to submission. the legacy libraries from this period proved to be multimillion dollar problems as hundreds of thousands of samples had to be purified, reweighed, or simply discarded. 70,79-81 but this cost more than outweighed the cost of screening bad samples, which has been estimated to be as high as $4 million over 5 years for every 10% of the samples that are bad. 111 the good news is that this has left the industry with better libraries and, more important, a dedication to sample quality. So you now have high-purity samples in your library and know the structures are correct. how are you going to store them to ensure structural integrity? compound degradation is not a serious problem for dry samples. they are simply stored neat in dry conditions and are stable for very long periods of time. the real "problem child" of cm is the liquid phase compound library. for decades now, dmSo has been known and used as the best universal solvent. [63] [64] [65] [66] [67] [68] although significant effort was expended in the 1980s to try and find a superior solvent system, the most common storage and handling solvent for potentially pharmacologically active compounds remains a solvent that carries such agents freely across the skin and into the bloodstream. but that is a safety issue, not one dealing with error, and should be dealt with elsewhere. the real problem with dmSo is its propensity to absorb water and change its physical properties and solvation capability. 63, 64 for example, the freezing point of dmSo shifts by over 70 °c with the addition/absorption of 30% water, 63 and the molecular clusters formed by the strong interaction between dmSo and water molecules result in variations of several other physicochemical properties of dmSo (see catalan et al. 64 and references therein). So how should libraries be stored to best ensure the stability of their precious compounds? there have been several studies on the stability of compounds under various storage conditions, [71] [72] [73] 87, 93 but this remains an area where no real industry standard exists. novartis 36 chooses to store its compounds in a 10% water/dmSo solution at 4 °c, whereas others store compounds at room temperature (e.g., ncgc 57 ) or dried 38 to avoid freeze thaw. the most common method of storage is -20 °c (e.g., gSK, 28 pfizer, 29 Wyeth, 52 Queensland compound library 53 ) or 4 °c (e.g., merck, 34, 45, 47 biogen, 87 bmS 56 ) in dmSo as dry as possible. a basic rule of precision is that if you are consistent in how you handle your samples from run to run, the results will agree from run to run (see process error below).
finally, the postproduction handling of compounds and their formulation after leaving cm is an area that can introduce significant chemical error. this is often confused with biological error because it happens in the testing lab. in htS or industrialized lead optimization (lo) processes, compounds are usually handled by standardized methods using the same good practices that have been developed in cm settings. but the customer base for cm has expanded to include laboratories that are less experienced in handling compounds. in these cases, error can be introduced unintentionally by such simple storage mistakes as refrigerating aqueous diluted samples, thereby subjecting the compounds to ideal crystallization conditions. these errors can be significant and usually manifest themselves as run-to-run variation.
a less obvious problem that can plague cm is related to the sample solubility. 74, 75, 82, 83, 88, 90, 92 how much of the sample you have carefully weighed and tracked actually dissolves in buffer, and how much does that vary as it is tested in varying biological systems that may include variations in ph, protein and serum levels, detergent, or ionic strength? again, the answer is not yet clear, nor is there an industry standard, but more and more companies are realizing this source of error in both htS and lead optimization, where it is vital that accurate data are used to determine SaR as well as a structure-properties relationship (SpR) and make synthesis decisions.
PROCESS ERROR
process error can be divided into 2 major sources: tracking errors and dispensation errors. as mentioned above, managing the identity of the compounds was a driving force behind the creation of cm systems. but these systems are only rarely fully integrated, and any time a sample is transferred between people, devices, laboratories, or systems, potential error is introduced. if sample ids or information must be manually entered when 
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Tracking Contamination Weighing and liquid handling Storage Analytical measurement registered or transferred, error is almost guaranteed. because of this, barcoding has become ubiquitous in cm and htS and is also widely employed in automated lo settings. 105 but error can still be introduced by simple data system hang-ups, system bugs, and manual entry requirements. these errors are infrequent in the transfer to htS laboratories but are compounded when samples are shared globally in an environment where vials and plates may be tested in laboratories that are not equipped with automated systems and may not even employ barcode scanners. a source of potential error that is within cm's domain is error related to compound dispensation. this includes gross weighing and liquid handling variance resulting from contamination and/or carryover. an often overlooked process is weighing of solid samples to make stock solutions. even when using precision balances calibrated on a regular basis and where accuracy is very good, the precision with which small amounts of sample (~1 mg) are weighed can be significantly high. for example, a ±10% precision in weighing will translate directly into at least the same error in the final concentration of the compound solution 41, 80 and may significantly exceed that level when other process-related error is also factored into the system. Similarly, poorly calibrated liquid-handling devices can introduce significant errors. 31, 40, 44, 62 most liquid-handling systems specify the ability to pipette with coefficients of variation of 10% or less. experienced engineers and cm professionals know that these are considered upper limits for a well-tuned system and that much lower variance levels can be achieved and maintained by applying rigorous maintenance and validation procedures. however, to maintain reasonable error rates, liquid handlers must be carefully maintained. periodic maintenance must be performed on a specified schedule, and equipment problems must be remedied immediately to maintain "in spec" dispensing. the systems should also be validated on a much more frequent basis to ensure proper performance, often weekly or daily. the potential error from dispensing is compounded because the volumes dispensed in cm are continually decreasing. 55, 58, 61 as long as the liquid-handling systems are still used within their specified dispense volume ranges, this should not cause a problem, but it is very tempting to simply push the limits of existing pipettors to avoid capital expenditure. as one approaches the limits of these systems, additional care and maintenance must be employed to avoid increased error rates. however, as dispense volumes fall below 100 nl, there are exceptions to this rule. Systems that dispense fixed nanoliter droplets may be internally calibrated, and error rates actually can be compounded in larger volumes because of the sheer number of droplets required to make up a microliter volume.
although error can be introduced from dispensation itself, the most common source of contamination is liquid-handling systems. tip washing is often employed in liquid handlers. if one is dispensing a potent compound (1 nm ic 50 ) that will be tested at a nominal concentration of 10 µm, then carryover of only 0.001% or 0.1 nl in a 10-µl assay volume can produce significant error in an assay. 62 this assumes that the biological system is such that potency curves extend over 3 logs of concentration, and significant effects (~20%) will be seen 1 log of concentration below the ic 50 .
THE IDEAL PROCESS
So given the potential sources of error described above, what would be the ideal system to integrate cm with biological testing? if one is allowed freedom from physical and budgetary constraints, the obvious choice would be to start with a pure solid sample with guaranteed correct identity and weight, completely solubilize it directly into the assay buffer, and test it immediately. this also assumes that the sample will not undergo any degradation in the assay and will be fully biologically available to the system. unfortunately, reality always intrudes on ideal situations, and we must begin to consider the actual situation. first, let us look at the physical constraints introduced by the drug discovery process:
• Samples must be transferred between locations, and positive sample tracking must be maintained. • Samples will be solubilized in a solvent other than the assay buffer. • automation will be employed at multiple points in the process. • the error resulting from biological assays cannot be ignored.
given these constraints, this idealized process can be overlaid with the cm process ( Fig. 3, inner circle) . although still highly idealized (and free from major portions of reality), this process flow captures the major steps in moving a compound from synthesis through testing to data capture.
When compared with the ideal process ( Fig. 3, outer circle) , the real world in cm does differ from the ideal, but the improvements instituted over the past decade are leading ever closer to it. the drive to quality that was described earlier has led to solutions to many of the problems associated with compound management, storage, and transfer in the past century, but there are many areas for improvement. Some will be solved by technological advancement, some by process improvement, and some may never be solved, but the industry appears to be dedicated to moving away from the days when cm was seen as an afterthought and a career killer to recognition of cm as a profession 26 in its own right. one could argue that cm will follow the same trajectory as the htS laboratories that it spun off from. htS professionals have gained recognition as a valued discipline, and the techniques developed for htS have been widely accepted into other areas of discovery. it is hoped that cm will see the same acceptance of techniques across an even broader area.
